In this double-blind , placebo-controlled , phase 3 trial , patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole ( 15 mg/kg per day ) plus praziquantel ( 50 mg/kg per day ) , standard albendazole ( 15 mg/kg per day ) , or increased dose albendazole ( 225 mg/kg per day ) .